During the past 7 years I have been focused on developing novel strategies for the treatment of solid tumors, mainly using gene and cell therapy. During my master degree I studied the role of the interaction of oncolytic adenoviruses with erythrocytes for the tumor bioavailability. The results from this work lead to the publication of one article (LA Rojas, Cancer Gene Therapy 2017). I later moved to work as a research scientist at PsiOxus Therapeutics (United Kingdom), to characterize the interaction of oncolytic viruses with the tumor immune microenvironment. During that time, I yielded significant data used for peer-reviewed scientific papers (Dyer, Mol Ther Oncolytics 2016 and Marino, PLoS One 2017), relevant international conferences (EMBO, ACCR, etc), intellectual property patents and for signing a major collaboration agreement with Bristol Meyer Squibb (resulting in the NCT02636036 clinical trial).All along, I was funded by a Marie Curie grant associated to Initial Training Network ADVance 7th Framework Project for the investigation of Adenovirus as novel clinical treatments. Thanks to this program I had the opportunity to cooperate with recognized academic and industry labs across Europe and US, building on my professional network. The Marie Curie grant also allowed me to perform my PhD at the University of Oxford for the study of oncolytic adenoviruses, under the supervision of Professor Len Seymour.On May 2018, I was hired by Dr. Sonia Guedan as PostDoc fellow to develop new chimeric antigen receptors (CAR) to improve the persistence of CAR T cells in solid malignancies as well as to improving their anti-tumor efficacy. Since, we have incorporated and trained three PhD students; we have published a useful review that guides into the design of chimeric antigen receptors (Guedan, Mol Ther Methods Clin Dev 2019) and a book chapter to identify the tonic singling in CAR T Cells (Calderon, Methods in Molecular Biology 2020).